● pepmg Research Desk · Peer-reviewed evidence review
What the research says about cortagen
A neutral summary of the peer-reviewed literature on cortagen, a synthetic brain-cortex-derived tetrapeptide bioregulator studied only in animal and in-vitro models, including ex-vivo human-cell cultures. There are no controlled human trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Cortagen is described in the literature as a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro, obtained by directed synthesis based on the natural brain-cortex peptide preparation Cortexin [1][2].
- The evidence is entirely preclinical: animal studies report effects on brain-cortex tissue explants, sciatic-nerve regeneration measures, brain oxidative-stress markers, and behavior in rat ischemia models [1][3][4][5].
- In-vitro work, including cultures of ex-vivo human lymphocytes from elderly donors, reports immune-gene and chromatin changes; there are no controlled human trials of cortagen as an administered compound, and the work is essentially from a single research group [6][7][8][9].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What cortagen is
Cortagen is characterized in the literature as a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro, described as obtained by directed synthesis based on amino-acid analysis of the natural brain-cortex peptide preparation Cortexin [2]. It is one of a family of Khavinson-type short peptide bioregulators (cytogens), and organ-culture work reports that these peptides act tissue-specifically, with cortagen studied in the context of brain-cortex tissue [1].
Cortagen is a research compound, not an approved medicine. Material sold by third-party research-chemical vendors is offered for laboratory and research use only.
What the research has measured
Preclinical onlyThe evidence for cortagen is entirely preclinical. In organotypic culture, cortagen was reported to stimulate the growth of explants from rat brain cortex, a tissue-specific effect matching the source tissue of its parent preparation [1]. In a rat sciatic-nerve model, intramuscular cortagen after transection and suturing was reported to increase the growth rate and conduction velocity of the regenerating nerve fibers by 27% and 40%, respectively [5]. In a chronic brain-ischemia model, cortexin and cortagen were reported to accelerate recovery of behavior in ischemic rats and to prevent excessive activation of lipid peroxidation in brain tissue [4].
Other animal work measured oxidative and gene-expression endpoints. Injections of epithalon and cortagen to rats were reported to decrease lipid-peroxidation products and reduce oxidative modification of proteins in serum and cerebral cortex [3]. A cDNA-microarray study in mouse heart reported that a short course of cortagen altered the expression of roughly 110 known genes across functional categories [2]. These are measured endpoints in animal models.
In-vitro immune assays describe modest or null effects. In mouse thymocytes, cortagen produced no comitogenic effect on proliferation, in contrast to other short peptides tested [6], and in splenocytes cortagen produced a less pronounced effect on interleukin-2 mRNA synthesis than the comparator peptides [7]. These are cell-model observations, not clinical outcomes.
A separate line of work used cultures of ex-vivo human lymphocytes from elderly donors. In lymphocytes from individuals aged 75-88, cortagen was among short peptides reported to induce decondensation of densely packed chromatin and activation of ribosomal genes [8][9]. This is in-vitro work on human cells in culture, not administration of cortagen to people.
What the trials report on safety and adverse events
Preclinical onlyThere are no controlled human trials of cortagen, and the abstracts reviewed here contain no human adverse-event data. Nothing in this literature reports rates of side effects in people.
The preclinical abstracts describe measured biological effects rather than a formal toxicity profile. In mouse thymocytes, cortagen produced no comitogenic effect on proliferation [6], and in rat models cortagen was reported to reduce lipid-peroxidation products and oxidative protein modification [3][4]. These are measured effects in animal and cell models, not a human safety characterization, and the abstracts do not report toxicity testing.
Because the data are preclinical, nothing here should be read as a safety statement for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for cortagen is characterized as preclinical: it consists of animal studies (nerve regeneration, brain ischemia, oxidative-stress and gene-expression endpoints) and in-vitro work, including cultures of ex-vivo human lymphocytes, with no controlled human trials of cortagen as an administered compound and a literature drawn essentially from a single research group [1][3][5][8]. "Preclinical" describes the design and scope of the published studies, not an endorsement, and the scope is narrow: the human-cell findings are in cultured cells, not in people.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 9
- Tissue-specific effects of peptides.
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray.
- Effects of bioactive tetrapeptides on free-radical processes.
- [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia].
- Effect of tetrapeptide cortagen on regeneration of sciatic nerve.
- Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway.
- In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes.
- EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.
- Effects of short peptides on lymphocyte chromatin in senile subjects.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.